Logo image of AURA

AURA BIOSCIENCES INC (AURA) Stock Fundamental Analysis

NASDAQ:AURA - Nasdaq - US05153U1079 - Common Stock - Currency: USD

5.69  -0.02 (-0.35%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to AURA. AURA was compared to 568 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for AURA as it has an excellent financial health rating, but there are worries on the profitability. AURA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year AURA has reported negative net income.
AURA had a negative operating cash flow in the past year.
In the past 5 years AURA always reported negative net income.
In the past 5 years AURA always reported negative operating cash flow.
AURA Yearly Net Income VS EBIT VS OCF VS FCFAURA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

With a Return On Assets value of -47.63%, AURA perfoms like the industry average, outperforming 50.00% of the companies in the same industry.
The Return On Equity of AURA (-57.19%) is better than 61.44% of its industry peers.
Industry RankSector Rank
ROA -47.63%
ROE -57.19%
ROIC N/A
ROA(3y)-34.61%
ROA(5y)-53.81%
ROE(3y)-40.36%
ROE(5y)-61.34%
ROIC(3y)N/A
ROIC(5y)N/A
AURA Yearly ROA, ROE, ROICAURA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for AURA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AURA Yearly Profit, Operating, Gross MarginsAURA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

Compared to 1 year ago, AURA has more shares outstanding
The number of shares outstanding for AURA has been increased compared to 5 years ago.
There is no outstanding debt for AURA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
AURA Yearly Shares OutstandingAURA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
AURA Yearly Total Debt VS Total AssetsAURA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

An Altman-Z score of 1.99 indicates that AURA is not a great score, but indicates only limited risk for bankruptcy at the moment.
AURA has a Altman-Z score of 1.99. This is in the better half of the industry: AURA outperforms 73.24% of its industry peers.
There is no outstanding debt for AURA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1.99
ROIC/WACCN/A
WACCN/A
AURA Yearly LT Debt VS Equity VS FCFAURA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

A Current Ratio of 10.77 indicates that AURA has no problem at all paying its short term obligations.
The Current ratio of AURA (10.77) is better than 81.87% of its industry peers.
AURA has a Quick Ratio of 10.77. This indicates that AURA is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 10.77, AURA belongs to the top of the industry, outperforming 82.04% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 10.77
Quick Ratio 10.77
AURA Yearly Current Assets VS Current LiabilitesAURA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

0

3. Growth

3.1 Past

AURA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 11.62%, which is quite good.
EPS 1Y (TTM)11.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to decrease by -12.56% on average over the next years. This is quite bad
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-25.81%
EPS Next 2Y-15.99%
EPS Next 3Y-12.56%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AURA Yearly Revenue VS EstimatesAURA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
AURA Yearly EPS VS EstimatesAURA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

AURA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AURA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AURA Price Earnings VS Forward Price EarningsAURA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AURA Per share dataAURA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2 3

4.3 Compensation for Growth

A cheap valuation may be justified as AURA's earnings are expected to decrease with -12.56% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-15.99%
EPS Next 3Y-12.56%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AURA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AURA BIOSCIENCES INC

NASDAQ:AURA (4/23/2025, 2:40:26 PM)

5.69

-0.02 (-0.35%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-24 2025-03-24/amc
Earnings (Next)05-08 2025-05-08/amc
Inst Owners82.83%
Inst Owner Change0.06%
Ins Owners3.14%
Ins Owner Change29.28%
Market Cap285.81M
Analysts83.08
Price Target22.44 (294.38%)
Short Float %2.32%
Short Ratio7.79
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-4.21%
Min EPS beat(2)-14.95%
Max EPS beat(2)6.54%
EPS beat(4)3
Avg EPS beat(4)5.4%
Min EPS beat(4)-14.95%
Max EPS beat(4)19.34%
EPS beat(8)6
Avg EPS beat(8)2.31%
EPS beat(12)8
Avg EPS beat(12)1.24%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.76%
PT rev (3m)-0.9%
EPS NQ rev (1m)-4.58%
EPS NQ rev (3m)-9.16%
EPS NY rev (1m)-5.15%
EPS NY rev (3m)-5.58%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.88
P/tB 1.88
EV/EBITDA N/A
EPS(TTM)-1.75
EYN/A
EPS(NY)-2.35
Fwd EYN/A
FCF(TTM)-1.61
FCFYN/A
OCF(TTM)-1.59
OCFYN/A
SpS0
BVpS3.03
TBVpS3.03
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -47.63%
ROE -57.19%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-34.61%
ROA(5y)-53.81%
ROE(3y)-40.36%
ROE(5y)-61.34%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 102.45%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.77
Quick Ratio 10.77
Altman-Z 1.99
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)83.19%
Cap/Depr(5y)119.79%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)11.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y-25.81%
EPS Next 2Y-15.99%
EPS Next 3Y-12.56%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-13.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-25.56%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-24.99%
OCF growth 3YN/A
OCF growth 5YN/A